期刊文献+

晚期食管鳞癌二线药物治疗的研究进展 被引量:11

下载PDF
导出
摘要 食管癌是全球尤其是在我国发病率和死亡率均较高的恶性肿瘤。我国食管癌的主要病理类型为鳞癌,但鳞癌手术后复发率和转移率仍较高,且预后差,患者需要进一步接受以化疗为主的综合治疗。晚期食管鳞癌一线治疗多采用含铂方案,但治疗失败后患者的中位生存时间不到1年,而二线药物治疗无标准的治疗方案。本文系统总结了国内外针对食管鳞癌二线治疗的研究结果,以期为临床治疗提供选择依据。
作者 王玺 黄镜
出处 《癌症进展》 2015年第4期357-360,共4页 Oncology Progress
  • 相关文献

参考文献27

  • 1Hayashi K, Ando N, Watanabe H, et al. Phase II evanlu- ation of protracted infusion of eisplatin and 5-fluoroura- cil in advanced squamous cell carcinoma of the esopha- gus: a Japan Esophageal Ontology Group (JEOG) Trial (JCOG9407)[J]. Jpn J Clin Oncol, 2001, 31(9): 419-423.
  • 2Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) ver- sus cisplatin alone in advanced squamous cell oesopha- geal cancer[J]. Eur J Cancer, 1997, 33(8): 1216-1220.
  • 3Huang J, Zhou Y, Zhang H, et al. A phase II study of bi- weekly paclitaxel and cisplatin chemotherapy for recur- rent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy [J]. Med Oncol, 2013, 30(1): 343.
  • 4Burkart C, Bokemeyer C, Klump B, et al. A phase II tri- al of weekly irinotecan in cisplatin-refractory esophageal cancer[J]. Anticancer Res, 2007, 27(4C): 2845-2848.
  • 5Akutsu Y, Kono T, Uesato M, et al. S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma[J]. Ontol- ogy, 2013, 84(5): 305-310.
  • 6Heath El, Urba S, Marshall J, et al. Phase II trial of docetaxel chemotherapy in patients with incurable adeno- carcinoma of the esophagus[J]. Invest New Drugs, 2002, 20(1): 95-99.
  • 7Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer[J]. Ann Oncol, 2004, 15(6): 955-959.
  • 8Shirakawa T, Kato K, Nagashima K, et al. A retrospec- tive study of docetaxel or paclitaxel in patients with ad- vanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum- based chemotherapy[J]. Cancer Chemother Pharmacol, 2014, 74(6): 1207-1215.
  • 9Mizota A, Shitara K, Kondo C, et al. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy[J]. Oncology, 2011, 81(3-4): 237-242.
  • 10Tanaka T, Fujita H, Sueyoshi S, et al. Second-line com- bination chemotherapy with docetaxel for cisplatin-pre- treated refractory metastatic esophageal cancer: a pre- liminary report of initial experience[J]. Chemotherapy, 2007, 53(6): 449-453.

同被引文献79

引证文献11

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部